Phase 3 Antipsychotic Candidate Pimavanserin Fails to Achieve Primary Efficacy Endpoint
March 12th 2024Pimavanserin failed to achieve the primary efficacy endpoint of control of negative symptoms in patients with schizophrenia in the ADVANCE-2 trial. Acadia Pharmaceuticals will not pursue further research.